Hospira controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile2 entries
2015
Infusion-pump cybersecurity vulnerabilities
Researchers identified serious firmware vulnerabilities in certain Hospira patient-controlled analgesia infusion systems. FDA advisories warned of the risks and later recommended that healthcare providers stop using affected pumps.
2011
Sodium thiopental and capital punishment controversy
Hospira’s sodium-thiopental product was associated with lethal-injection protocols in some United States states. The company said it opposed capital-punishment use of its products and discontinued production after Italian authorities required safeguards against such use.